References
- Bohm, M., Vuppalanchi, R., and Chalasani, N, Drug-Induced Liver Injury Network (DILIN), 2016. Febuxostat-induced acute liver injury. Hepatology, 63 (3), 1047–1049.
- Chalasani, N., et al., United States Drug Induced Liver Injury Network, 2015. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology, 148 (7), 1340–1352.e7.
- Chalasani, N.P., Practice Parameters Committee of the American College of Gastroenterology, et al., 2014. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. The American Journal of Gastroenterology, 109 (7), 950–966; quiz 967.
- Farmer, A.D. and Brind, A., 2011. Drug-induced liver injury. Medicine, 39 (9), 536–540.
- FDA. 2019. FDA adds boxed warning for increased risk of death with gout medicine uloric (febuxostat). FDA Drug Safety Podcast Web site. Available from: https://www.fda.gov/drugs/fda-drug-safetypodcasts/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat.Published.
- Gonzalez, A.K., and Lefkowitch, J.H., 2017. Heart disease and the liver: pathologic evaluation. Gastroenterology Clinics of North America, 46 (2), 421–435.
- Hayashi, P.H., and Fontana, R.J., 2014. Clinical features, diagnosis, and natural history of drug-induced liver injury. Seminars in Liver Disease, 34 (2), 134–144.
- Ito, K., et al., 2014. Acute severe liver dysfunction induced by febuxostat in a patient undergoing hemodialysis. CEN Case Reports, 3 (2), 158–161.
- Lee, J.S., et al., 2019. Hepatic safety of febuxostat compared with allopurinol in gout patients with fatty liver disease. The Journal of Rheumatology, 46 (5), 527–531.
- Leise, M.D., Poterucha, J.J., and Talwalkar, J.A., 2014. Drug-induced liver injury. Mayo Clinic Proceedings, 89 (1), 95–106.
- Mackenzie, I.S., et al., 2020. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. The Lancet, 396 (10264), 1745–1757.
- Radovanovic, M., et al., 2018. Idiosyncratic drug-induced liver injury due to ciprofloxacin: A report of two cases and review of the literature. American Journal of Case Reports, 19, 1152–1161.
- Watkins, P.B., 2011. Drug safety sciences and the bottleneck in drug development. Clinical Pharmacology and Therapeutics, 89 (6), 788–790.
- White, W.B., et al., 2018. Cardiovascular safety of febuxostat or allopurinol in patients with gout. New England Journal of Medicine, 378 (13), 1200–1210.
- Xanthopoulos, A., et al., 2019. Heart failure and liver disease: cardiohepatic interactions. JACC, 7 (2), 87–97.